OncoMatch/Clinical Trials/NCT06438250

68Ga-JH04 PET/CT: Dosimetry and Biodistribution Studies

Is NCT06438250 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies 68Ga-JH04 for malignant neoplasm.

Early Phase 1RecruitingFirst Affiliated Hospital of Fujian Medical UniversityNCT06438250Data as of May 2026

Treatment: 68Ga-JH04 — 68Ga-JH04 is a novel radiotracer targeting fibroblast activation protein (FAP). In this study, we observed the safety, biodistribution, and radiation dosimetry of 68Ga-JH04 in patients with different types of cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify